Mankind Pharma Ltd (MANKIND)
₹2,507.20
Mkt cap
₹1.04L Cr
P/E ratio
51.40
P/B
6.35
Div yield
0.04%
ROE
13.10%
ROCE
13.50%
EPS (TTM)
₹48.78
Book value
₹395
52W range
1,927–2,671
Sector
Healthcare
Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products. [1]
Health check
Mixed
ValuationExpensive
ProfitabilityAverage
GrowthModerate
TechnicalsBullish
52-week range
−6.11% from high₹2,507
₹1,927+30.08% from low₹2,671
Current
₹2,507.20
Prev close
₹2,512.00
Day
−0.19%
Price performance
1D
−0.19%
1W
−2.28%
1M
+1.82%
3M
+10.58%
6M
+18.02%
1Y
−5.01%
YTD
+13.82%
Financials
FRevenue, profit & margin
P/E ratio
51.4×
MANKIND is 51% above the sector median of 34.0×
MANKIND51.4×
Sector median34.0×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,053 | 2,579 | 2,708 | 2,607 | 2,422 | 2,868 | 3,061 | 3,199 | 3,079 | 3,570 | 3,697 | 3,567 | 3,443 | |
| Expenses | 1,636 | 1,924 | 2,025 | 2,000 | 1,836 | 2,196 | 2,214 | 2,383 | 2,396 | 2,724 | 2,776 | 2,648 | 2,513 | |
| Operating Profit | 417 | 655 | 683 | 606 | 586 | 672 | 847 | 816 | 683 | 847 | 921 | 919 | 930 | |
| OPM % | 20% | 25% | 25% | 23% | 24% | 23% | 28% | 26% | 22% | 24% | 25% | 26% | 27% | |
| Other Income | 50 | 63 | 63 | 75 | 94 | 108 | 109 | 87 | 249 | 83 | 94 | -31 | 94 | |
| Interest | 5 | 6 | 9 | 9 | 9 | 11 | 7 | 221 | 191 | 171 | 170 | 157 | 142 | |
| Depreciation | 85 | 87 | 96 | 110 | 100 | 103 | 100 | 187 | 231 | 219 | 222 | 223 | 223 | |
| Profit before tax | 377 | 624 | 641 | 562 | 572 | 666 | 849 | 495 | 511 | 540 | 624 | 509 | 659 | |
| Tax % | 22% | 21% | 20% | 18% | 17% | 18% | 22% | 22% | 17% | 18% | 17% | 19% | 15% | |
| Net Profit | 294 | 494 | 511 | 460 | 477 | 543 | 659 | 385 | 425 | 445 | 520 | 414 | 559 | |
| EPS in Rs | 7.13 | 12.15 | 12.51 | 11.33 | 11.76 | 13.39 | 16.31 | 9.22 | 10.20 | 10.62 | 12.39 | 9.90 | 13.43 | |
| Raw PDF |
Earnings
EResults dates & reactionsNext results
30 Jul '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.04% · closed higher next day 7 of last 13
| Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 2 Aug '23◦ | 31 Oct '23◦ | 31 Jan '24◦ | 15 May '24◦ | 31 Jul '24◦ | 5 Nov '24◦ | 24 Jan '25 | 21 May '25◦ | 31 Jul '25◦ | 6 Nov '25◦ | 3 Feb '26◦ | 19 May '26◦ |
| Earnings day | +9.10% | +0.12% | +2.32% | −4.48% | −1.15% | +1.27% | −4.86% | −3.64% | −0.04% | −2.05% | −3.39% | +3.66% |
| +1 day | +8.09% | +3.39% | +1.77% | −4.57% | −1.38% | +0.47% | −6.87% | −3.91% | +2.40% | −3.14% | −3.80% | +0.86% |
| +5 days | +5.85% | +5.86% | +12.49% | −4.14% | +2.18% | −6.71% | −7.58% | −2.75% | −3.90% | −1.82% | −3.50% | −2.90% |
| +15 days | +2.62% | +11.05% | +9.46% | −1.57% | +16.49% | −5.64% | −5.08% | −5.59% | −0.39% | −2.52% | −0.32% | −4.81% |
| +30 days | +1.49% | +8.69% | +9.19% | −2.81% | +23.21% | +3.35% | −12.11% | −6.70% | +0.10% | −5.93% | −7.48% | +1.44% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Jun 202672.63%Promoter
Promoters72.63%0.03
FIIs9.45%0.79
DIIs15.39%0.93
Public2.53%0.10
Ownership trend
Peers
P7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,723 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.10 | 1,88,697 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,559 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports4
Concall transcripts36
TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025TranscriptJan 2025PPTJan 2025TranscriptNov 2024PPTNov 2024PPTSep 2024PPTAug 2024TranscriptAug 2024PPTAug 2024TranscriptAug 2024PPTAug 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 17 Jul - Please find attached intimation regarding investor conference call for Q1FY27.Board Meeting Intimation for Approval Of Financial Results 16 Jul - Board meeting on July 30, 2026 to approve Q1 FY27 standalone and consolidated results; trading window closed till August 1, 2026.Announcement under Regulation 30 (LODR)-Diversification / Disinvestment 11 Jul - Board approved selling Broadway Hospitality stake for ₹49 crore and setting up Netherlands WOS with up to Euro 5 million investment.Announcement under Regulation 30 (LODR)-Acquisition 11 Jul - Board approved sale of Broadway for ₹49 crore and Netherlands WOS investment up to Euro 5 million.Board Meeting Outcome for Outcome Of Board Meeting 11 Jul - Board approved sale of Broadway Hospitality stake for ₹49 crore and Netherlands WOS for R&D investments.